Symbols / VERA Stock $40.27 +0.52% Vera Therapeutics, Inc.
VERA (Stock) Chart
About
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 2.89B | Enterprise Value | 2.24B | Income | -299.62M | Sales | — | Book/sh | 8.48 | Cash/sh | 10.01 |
| Dividend Yield | — | Payout | 0.00% | Employees | 249 | IPO | — | P/E | — | Forward P/E | -13.23 |
| PEG | — | P/S | — | P/B | 4.75 | P/C | — | EV/EBITDA | -7.10 | EV/Sales | — |
| Quick Ratio | 13.43 | Current Ratio | 13.63 | Debt/Eq | 12.79 | LT Debt/Eq | — | EPS (ttm) | -4.66 | EPS next Y | -3.04 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-05 | ROA | -28.36% | ROE | -50.71% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 71.71M | Shs Float | 51.53M | Short Float | 15.51% |
| Short Ratio | 7.55 | Short Interest | — | 52W High | 56.05 | 52W Low | 18.76 | Beta | 1.17 | Avg Volume | 1.17M |
| Volume | 651.24K | Target Price | $79.00 | Recom | Strong_buy | Prev Close | $40.06 | Price | $40.27 | Change | 0.52% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | up | Wolfe Research | Peer Perform → Outperform | $88 |
| 2026-03-02 | main | HC Wainwright & Co. | Buy → Buy | $110 |
| 2025-12-19 | main | B of A Securities | Buy → Buy | $66 |
| 2025-12-19 | main | Goldman Sachs | Buy → Buy | $95 |
| 2025-12-19 | main | JP Morgan | Overweight → Overweight | $96 |
| 2025-12-11 | main | Wedbush | Neutral → Neutral | $33 |
| 2025-12-08 | main | Evercore ISI Group | Outperform → Outperform | $97 |
| 2025-12-05 | main | TD Cowen | Buy → Buy | $73 |
| 2025-11-10 | main | HC Wainwright & Co. | Buy → Buy | $90 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $52 |
| 2025-10-16 | init | B of A Securities | — → Buy | $48 |
| 2025-08-07 | main | JP Morgan | Overweight → Overweight | $53 |
| 2025-08-04 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2025-06-02 | main | Scotiabank | Sector Outperform → Sector Outperform | $65 |
| 2025-06-02 | main | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-05-12 | main | Scotiabank | Sector Outperform → Sector Outperform | $55 |
| 2025-05-07 | main | Wedbush | Neutral → Neutral | $26 |
| 2025-05-07 | main | Cantor Fitzgerald | Overweight → Overweight | $100 |
| 2025-03-04 | main | JP Morgan | Overweight → Overweight | $71 |
| 2025-02-27 | main | Guggenheim | Buy → Buy | $61 |
- Nvidia Stock Today: NVDA Rises as Google Unveils New AI Chips, Still Backs Vera Rubin - TechStock² hu, 23 Apr 2026 13
- Vera Therapeutics Grants Inducement Awards to New Employees Under 2024 Inducement Plan - Quiver Quantitative Fri, 10 Apr 2026 20
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - Yahoo Finance Mon, 08 Dec 2025 08
- VERA (Vera Therapeutics Inc.) drops 2.78% after reporting a wider than expected Q4 2025 loss that missed analyst estimates. - Hot Community Stocks - Xã Thanh Hà Wed, 22 Apr 2026 21
- Nvidia stock holds steady as new production ramps for Vera Rubin integrated - Traders Union ue, 21 Apr 2026 14
- Vera Therapeutics, Inc. Class A Common Stock (VERA) Stock Price Today & Analysis - Gotrade Fri, 09 Jan 2026 20
- Vera Therapeutics issues stock awards to 89 new employees - Stock Titan Fri, 10 Apr 2026 07
- Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock - Investing.com Wed, 15 Apr 2026 21
- Vera Bradley’s Peanuts Country Club Collection is swinging out of stock: shop remaining styles - NJ.com Fri, 17 Apr 2026 17
- Nvidia Stock Ticks Up as Bernstein Analyst Says Vera Rubin Will Deliver ‘5x More Inference Performance’ - TipRanks Fri, 17 Apr 2026 13
- Vera Bradley Scraps 'Poison Pill' Defense Amid Stock Surge - BriefGlance Fri, 17 Apr 2026 22
- Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock at $42.50 per Share - Quiver Quantitative Wed, 10 Dec 2025 08
- Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price Surge - Yahoo Finance Fri, 10 Apr 2026 07
- Vera Bradley board scraps takeover defense six months early - Stock Titan Fri, 17 Apr 2026 20
- Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? - Yahoo Finance Wed, 14 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
315.47
+88.71%
|
167.17
+63.87%
|
102.01
+12.22%
|
90.90
|
| Research And Development |
|
215.26
+70.61%
|
126.17
+61.29%
|
78.22
+13.38%
|
68.99
|
| Selling General And Administration |
|
100.22
+144.44%
|
41.00
+72.35%
|
23.79
+8.57%
|
21.91
|
| General And Administrative Expense |
|
100.22
+144.44%
|
41.00
+72.35%
|
23.79
+8.57%
|
21.91
|
| Other Gand A |
|
100.22
+144.44%
|
41.00
+72.35%
|
23.79
+8.57%
|
21.91
|
| Total Expenses |
|
315.47
+88.71%
|
167.17
+63.87%
|
102.01
+12.22%
|
90.90
|
| Operating Income |
|
-315.47
-88.71%
|
-167.17
-63.87%
|
-102.01
-12.22%
|
-90.90
|
| Total Operating Income As Reported |
|
-315.47
-88.71%
|
-167.17
-63.87%
|
-102.01
-12.22%
|
-90.90
|
| EBITDA |
|
-291.62
-101.93%
|
-144.42
-56.66%
|
-92.18
-4.68%
|
-88.06
|
| Normalized EBITDA |
|
-291.62
-101.93%
|
-144.42
-56.66%
|
-92.18
-5.65%
|
-87.25
|
| Reconciled Depreciation |
|
0.47
+345.71%
|
0.10
+400.00%
|
0.02
+102.48%
|
-0.85
|
| EBIT |
|
-292.08
-102.10%
|
-144.52
-56.74%
|
-92.20
-4.70%
|
-88.06
|
| Total Unusual Items |
|
—
|
—
|
-0.05
+94.19%
|
-0.81
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
-0.05
+94.19%
|
-0.81
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Pretax Income |
|
-299.61
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Net Non Operating Interest Income Expense |
|
16.95
+29.49%
|
13.09
+212.14%
|
4.19
+453.17%
|
0.76
|
| Interest Expense Non Operating |
|
7.53
-1.25%
|
7.63
+101.43%
|
3.79
+281.65%
|
0.99
|
| Net Interest Income |
|
16.95
+29.49%
|
13.09
+212.14%
|
4.19
+453.17%
|
0.76
|
| Interest Expense |
|
7.53
-1.25%
|
7.63
+101.43%
|
3.79
+281.65%
|
0.99
|
| Interest Income Non Operating |
|
24.48
+18.18%
|
20.71
+159.61%
|
7.98
+355.94%
|
1.75
|
| Interest Income |
|
24.48
+18.18%
|
20.71
+159.61%
|
7.98
+355.94%
|
1.75
|
| Other Income Expense |
|
-1.09
-156.28%
|
1.94
+5.74%
|
1.83
+67.89%
|
1.09
|
| Other Non Operating Income Expenses |
|
-1.09
-156.28%
|
1.94
+5.74%
|
1.83
-3.63%
|
1.90
|
| Gain On Sale Of Security |
|
—
|
—
|
-0.05
+94.19%
|
-0.81
|
| Gain On Sale Of Business |
|
—
|
—
|
—
|
0.00
|
| Tax Provision |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.17
|
| Net Income Including Noncontrolling Interests |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Net Income From Continuing And Discontinued Operation |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Net Income Continuous Operations |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Normalized Income |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-8.57%
|
-88.42
|
| Net Income Common Stockholders |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Diluted EPS |
|
—
|
-2.75
-22.22%
|
-2.25
+32.84%
|
-3.35
|
| Basic EPS |
|
—
|
-2.75
-22.22%
|
-2.25
+32.84%
|
-3.35
|
| Basic Average Shares |
|
—
|
55.33
+29.55%
|
42.71
+60.73%
|
26.57
|
| Diluted Average Shares |
|
—
|
55.33
+29.55%
|
42.71
+60.73%
|
26.57
|
| Diluted NI Availto Com Stockholders |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
734.73
+12.06%
|
655.68
+273.51%
|
175.55
+33.56%
|
131.44
|
| Current Assets |
|
728.88
+11.93%
|
651.22
+278.56%
|
172.02
+36.85%
|
125.70
|
| Cash Cash Equivalents And Short Term Investments |
|
714.59
+11.51%
|
640.85
+298.75%
|
160.72
+40.18%
|
114.65
|
| Cash And Cash Equivalents |
|
354.73
+282.88%
|
92.65
+102.81%
|
45.68
+5.11%
|
43.46
|
| Cash Equivalents |
|
350.11
+290.19%
|
89.73
|
—
|
—
|
| Cash Financial |
|
4.62
+58.24%
|
2.92
|
—
|
—
|
| Other Short Term Investments |
|
359.86
-34.36%
|
548.21
+376.56%
|
115.03
+61.58%
|
71.19
|
| Receivables |
|
3.29
-12.93%
|
3.77
+636.91%
|
0.51
|
—
|
| Accrued Interest Receivable |
|
3.29
-12.93%
|
3.77
+636.91%
|
0.51
|
—
|
| Prepaid Assets |
|
8.47
+62.65%
|
5.21
-39.12%
|
8.56
-17.12%
|
10.33
|
| Other Current Assets |
|
2.54
+83.30%
|
1.38
-38.18%
|
2.24
+211.13%
|
0.72
|
| Total Non Current Assets |
|
5.85
+31.08%
|
4.46
+26.68%
|
3.52
-38.59%
|
5.74
|
| Net PPE |
|
3.30
-23.89%
|
4.33
+42.45%
|
3.04
-41.79%
|
5.22
|
| Gross PPE |
|
3.30
-23.89%
|
4.33
+42.45%
|
3.04
-41.79%
|
5.22
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
1.92
-42.97%
|
3.37
+14.34%
|
2.95
-42.99%
|
5.17
|
| Other Properties |
|
1.37
+43.13%
|
0.96
+943.48%
|
0.09
+80.39%
|
0.05
|
| Investments And Advances |
|
—
|
—
|
—
|
0.06
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
2.55
+1848.85%
|
0.13
-72.82%
|
0.48
-6.04%
|
0.51
|
| Total Liabilities Net Minority Interest |
|
130.21
+65.82%
|
78.53
+6.32%
|
73.86
+35.46%
|
54.53
|
| Current Liabilities |
|
53.45
+110.69%
|
25.37
+13.76%
|
22.30
-12.88%
|
25.60
|
| Payables And Accrued Expenses |
|
51.54
+132.84%
|
22.14
+11.42%
|
19.87
-13.45%
|
22.95
|
| Payables |
|
21.90
+177.86%
|
7.88
-39.57%
|
13.04
-11.69%
|
14.77
|
| Accounts Payable |
|
21.90
+185.69%
|
7.67
-31.06%
|
11.12
-7.28%
|
11.99
|
| Current Accrued Expenses |
|
29.64
+107.94%
|
14.25
+108.90%
|
6.82
-16.63%
|
8.18
|
| Current Debt And Capital Lease Obligation |
|
0.55
-62.98%
|
1.48
-39.12%
|
2.44
-7.90%
|
2.65
|
| Current Capital Lease Obligation |
|
0.55
-62.98%
|
1.48
-39.12%
|
2.44
-7.90%
|
2.65
|
| Other Current Liabilities |
|
1.37
-22.02%
|
1.75
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
76.76
+44.40%
|
53.16
+3.10%
|
51.56
+78.23%
|
28.93
|
| Long Term Debt And Capital Lease Obligation |
|
76.76
+44.40%
|
53.16
+3.67%
|
51.27
+79.02%
|
28.64
|
| Long Term Debt |
|
74.84
+47.65%
|
50.69
+1.62%
|
49.88
+101.04%
|
24.81
|
| Long Term Capital Lease Obligation |
|
1.92
-22.24%
|
2.47
+76.92%
|
1.40
-63.59%
|
3.83
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
604.52
+4.74%
|
577.15
+467.59%
|
101.69
+32.22%
|
76.91
|
| Common Stock Equity |
|
604.52
+4.74%
|
577.15
+467.59%
|
101.69
+32.22%
|
76.91
|
| Capital Stock |
|
0.07
+10.94%
|
0.06
+45.45%
|
0.04
+57.14%
|
0.03
|
| Common Stock |
|
0.07
+10.94%
|
0.06
+45.45%
|
0.04
+57.14%
|
0.03
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
71.27
+12.13%
|
63.56
+42.98%
|
44.45
+59.89%
|
27.80
|
| Ordinary Shares Number |
|
71.27
+12.13%
|
63.56
+42.98%
|
44.45
+59.89%
|
27.80
|
| Additional Paid In Capital |
|
1,364.53
+31.46%
|
1,037.95
+152.85%
|
410.49
+41.44%
|
290.22
|
| Retained Earnings |
|
-760.87
-64.96%
|
-461.25
-49.22%
|
-309.10
-45.04%
|
-213.11
|
| Gains Losses Not Affecting Retained Earnings |
|
0.79
+100.00%
|
0.39
+56.57%
|
0.25
+212.05%
|
-0.22
|
| Other Equity Adjustments |
|
0.79
+100.00%
|
0.39
+56.57%
|
0.25
+212.05%
|
-0.22
|
| Total Equity Gross Minority Interest |
|
604.52
+4.74%
|
577.15
+467.59%
|
101.69
+32.22%
|
76.91
|
| Total Capitalization |
|
679.36
+8.21%
|
627.84
+314.25%
|
151.56
+49.00%
|
101.72
|
| Working Capital |
|
675.43
+7.92%
|
625.85
+318.01%
|
149.72
+49.57%
|
100.10
|
| Invested Capital |
|
679.36
+8.21%
|
627.84
+314.25%
|
151.56
+49.00%
|
101.72
|
| Total Debt |
|
77.31
+41.49%
|
54.64
+1.73%
|
53.71
+71.67%
|
31.29
|
| Net Debt |
|
—
|
—
|
4.20
|
—
|
| Capital Lease Obligations |
|
2.47
-37.53%
|
3.95
+3.13%
|
3.83
-40.84%
|
6.48
|
| Net Tangible Assets |
|
604.52
+4.74%
|
577.15
+467.59%
|
101.69
+32.22%
|
76.91
|
| Tangible Book Value |
|
604.52
+4.74%
|
577.15
+467.59%
|
101.69
+32.22%
|
76.91
|
| Available For Sale Securities |
|
—
|
—
|
—
|
0.06
|
| Dueto Related Parties Current |
|
0.00
-98.62%
|
0.22
-88.73%
|
1.93
-30.72%
|
2.78
|
| Investmentin Financial Assets |
|
—
|
—
|
—
|
0.06
|
| Non Current Accrued Expenses |
|
—
|
0.00
-100.00%
|
0.29
+0.00%
|
0.29
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-241.10
-79.02%
|
-134.68
-46.10%
|
-92.18
-36.37%
|
-67.60
|
| Cash Flow From Continuing Operating Activities |
|
-241.10
-79.02%
|
-134.68
-46.10%
|
-92.18
-36.37%
|
-67.60
|
| Net Income From Continuing Operations |
|
-299.62
-96.92%
|
-152.15
-58.50%
|
-95.99
-7.79%
|
-89.06
|
| Depreciation Amortization Depletion |
|
0.47
+345.71%
|
0.10
+400.00%
|
0.02
+102.48%
|
-0.85
|
| Depreciation |
|
—
|
—
|
-4.09
-382.98%
|
-0.85
|
| Depreciation And Amortization |
|
0.47
+345.71%
|
0.10
+400.00%
|
0.02
+102.48%
|
-0.85
|
| Other Non Cash Items |
|
4.11
+42.87%
|
2.87
+12.71%
|
2.55
-56.51%
|
5.86
|
| Stock Based Compensation |
|
37.93
+82.32%
|
20.80
+81.00%
|
11.49
+29.32%
|
8.89
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
—
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
0.05
-94.19%
|
0.81
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
22.99
+764.36%
|
2.66
+145.69%
|
-5.82
-186.29%
|
6.75
|
| Change In Prepaid Assets |
|
-3.93
-500.41%
|
0.98
+467.05%
|
0.17
+102.11%
|
-8.18
|
| Change In Payables And Accrued Expense |
|
28.35
+659.09%
|
3.73
+220.95%
|
-3.09
-117.50%
|
17.64
|
| Change In Accrued Expense |
|
14.44
+100.92%
|
7.19
+424.51%
|
-2.21
-131.48%
|
7.04
|
| Change In Payable |
|
13.91
+502.84%
|
-3.45
-295.53%
|
-0.87
-108.23%
|
10.61
|
| Change In Account Payable |
|
13.91
+502.84%
|
-3.45
-295.53%
|
-0.87
-108.23%
|
10.61
|
| Change In Other Current Assets |
|
0.05
-85.47%
|
0.35
+233.97%
|
-0.26
-136.04%
|
-0.11
|
| Change In Other Current Liabilities |
|
-1.48
+38.39%
|
-2.41
+9.00%
|
-2.65
-1.65%
|
-2.60
|
| Investing Cash Flow |
|
194.29
+145.71%
|
-425.03
-977.91%
|
-39.43
+44.11%
|
-70.55
|
| Cash Flow From Continuing Investing Activities |
|
194.29
+145.71%
|
-425.03
-977.91%
|
-39.43
+44.11%
|
-70.55
|
| Net PPE Purchase And Sale |
|
-0.63
+35.19%
|
-0.97
-1442.86%
|
-0.06
-1.61%
|
-0.06
|
| Purchase Of PPE |
|
-0.63
+35.19%
|
-0.97
-1442.86%
|
-0.06
-1.61%
|
-0.06
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-0.63
+35.19%
|
-0.97
-1442.86%
|
-0.06
-1.61%
|
-0.06
|
| Net Investment Purchase And Sale |
|
195.72
+146.15%
|
-424.06
-977.16%
|
-39.37
+44.15%
|
-70.49
|
| Purchase Of Investment |
|
-310.45
+55.84%
|
-703.01
-212.55%
|
-224.93
-51.48%
|
-148.49
|
| Sale Of Investment |
|
506.16
+81.45%
|
278.96
+50.33%
|
185.56
+137.90%
|
78.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Net Other Investing Changes |
|
-0.80
|
—
|
—
|
—
|
| Financing Cash Flow |
|
308.90
-49.08%
|
606.67
+354.30%
|
133.54
+31.01%
|
101.93
|
| Cash Flow From Continuing Financing Activities |
|
308.90
-49.08%
|
606.67
+354.30%
|
133.54
+31.01%
|
101.93
|
| Net Issuance Payments Of Debt |
|
23.34
|
0.00
-100.00%
|
24.74
+24.85%
|
19.82
|
| Issuance Of Debt |
|
23.34
|
0.00
-100.00%
|
24.74
+24.85%
|
19.82
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
23.34
|
0.00
-100.00%
|
24.74
+24.85%
|
19.82
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
23.34
|
0.00
-100.00%
|
24.74
+24.85%
|
19.82
|
| Net Common Stock Issuance |
|
300.50
-52.49%
|
632.52
+450.02%
|
115.00
+33.52%
|
86.13
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
6.98
-47.95%
|
13.41
+1170.17%
|
1.06
-49.30%
|
2.08
|
| Net Other Financing Charges |
|
-21.92
+44.17%
|
-39.26
-441.12%
|
-7.26
-19.01%
|
-6.10
|
| Changes In Cash |
|
262.08
+458.03%
|
46.97
+2334.68%
|
1.93
+105.33%
|
-36.22
|
| Beginning Cash Position |
|
92.65
+102.81%
|
45.68
+4.41%
|
43.75
-45.29%
|
79.97
|
| End Cash Position |
|
354.73
+282.88%
|
92.65
+102.81%
|
45.68
+4.41%
|
43.75
|
| Free Cash Flow |
|
-241.73
-78.20%
|
-135.65
-47.06%
|
-92.24
-36.34%
|
-67.66
|
| Interest Paid Supplemental Data |
|
6.72
+1.02%
|
6.65
+98.45%
|
3.35
+274.53%
|
0.90
|
| Amortization Of Securities |
|
-6.98
+22.19%
|
-8.97
-102.39%
|
-4.43
|
—
|
| Common Stock Issuance |
|
300.50
-52.49%
|
632.54
+450.03%
|
115.00
+33.52%
|
86.13
|
| Issuance Of Capital Stock |
|
300.50
-52.49%
|
632.54
+450.03%
|
115.00
+33.52%
|
86.13
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Sale Of Intangibles |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-15 View
- 42026-03-25 View
- 42026-03-16 View
- 8-K2026-03-09 View
- 42026-03-09 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-25 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
- 42026-02-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|